Posted by Michael Wonder on 28 Aug 2021
MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway
27 August 2021 - The UK’s MHRA has approved UCB’s Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis.
In a statement, UCB said the MHRA decision makes Bimzelx one of the first medicines to be authorised through the new post-Brexit reliance licensing pathway.
